Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$53.22
-0.25-0.47%
Last update: Dec 1, 10:10 AM
Comments
Loading...
CRISPR Therapeutics Analyst Ratings and Price Targets | NASDAQ:CRSP | Benzinga
CRISPR Therapeutics AG has a consensus price target of $71.57 based on the ratings of 26 analysts. The high is $120 issued by Truist Securities on February 12, 2025. The low is $30 issued by TD Cowen on December 11, 2023. The 3 most-recent analyst ratings were released by Chardan Capital, Citigroup, and RBC Capital on November 26, 2025, November 12, 2025, and November 11, 2025, respectively. With an average price target of $67 between Chardan Capital, Citigroup, and RBC Capital, there's an implied 25.89% upside for CRISPR Therapeutics AG from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Citigroup
RBC Capital
Baird
Needham
1calculated from analyst ratings
Analyst Ratings for CRISPR Therapeutics
Get Alert | |||||
|---|---|---|---|---|---|
Nov 26, 2025 | 39.05% | Previous Buy Current Buy | |||
Nov 12, 2025 | 44.68% | Previous Buy Current Buy | |||
Nov 11, 2025 | -6.05% | Previous Sector Perform Current Sector Perform | |||
Nov 11, 2025 | -17.32% | Previous Neutral Current Neutral | |||
Nov 10, 2025 | 50.32% | Previous Buy Current Buy | |||
Oct 17, 2025 | 74.75% | Previous Buy Current Buy | |||
Oct 10, 2025 | 52.2% | Previous Buy Current Buy | |||
Sep 23, 2025 | 50.32% | Previous Buy Current Buy | |||
Sep 18, 2025 | 31.53% | Previous Initiates Current Overweight | |||
Aug 7, 2025 | 50.32% | Previous Buy Current Buy | |||
Aug 6, 2025 | 5.22% | Previous Equal-Weight Current Equal-Weight | |||
Aug 5, 2025 | 54.08% | Previous Buy Current Buy | |||
Aug 5, 2025 | -21.08% | Previous Sector Perform Current Sector Perform | |||
Jul 22, 2025 | 46.56% | Previous Buy Current Buy | |||
Jul 8, 2025 | 52.2% | Previous Buy Current Buy | |||
Jun 27, 2025 | -15.45% | Previous Buy Current Hold | |||
Jun 27, 2025 | 97.29% | Previous Overweight Current Overweight | |||
Jun 27, 2025 | 61.59% | Previous Market Outperform Current Market Outperform | |||
Jun 27, 2025 | 22.13% | Previous Buy Current Buy | |||
Jun 26, 2025 | 52.2% | Previous Buy Current Buy | |||
Jun 26, 2025 | 54.08% | Previous Buy Current Buy | |||
May 21, 2025 | 61.59% | Previous Market Outperform Current Market Outperform | |||
May 20, 2025 | 52.2% | Previous Buy Current Buy | |||
May 20, 2025 | 22.13% | Previous Buy Current Buy | |||
May 9, 2025 | -21.08% | Previous Equal-Weight Current Equal-Weight | |||
May 8, 2025 | -11.69% | Previous Neutral Current Neutral | |||
May 7, 2025 | 52.2% | Previous Buy Current Buy | |||
May 7, 2025 | 54.08% | Previous Buy Current Buy | |||
Apr 9, 2025 | 57.84% | Previous Buy Current Buy | |||
Feb 19, 2025 | — | — | Previous Neutral Current Neutral | ||
Feb 18, 2025 | 54.08% | Previous Buy Current Buy | |||
Feb 14, 2025 | -39.87% | Previous Underweight Current Underweight | |||
Feb 14, 2025 | 86.02% | Previous In-Line Current Outperform | |||
Feb 13, 2025 | 7.1% | Previous Neutral Current Neutral | |||
Feb 13, 2025 | 61.59% | Previous Market Outperform Current Market Outperform | |||
Feb 13, 2025 | -7.93% | Previous Hold Current Hold | |||
Feb 13, 2025 | 22.13% | Previous Buy Current Buy | |||
Feb 13, 2025 | 57.84% | Previous Buy Current Buy | |||
Feb 12, 2025 | 125.48% | Previous Buy Current Buy | |||
Feb 12, 2025 | -9.81% | Previous Sector Perform Current Sector Perform | |||
Feb 12, 2025 | 57.84% | Previous Buy Current Buy | |||
Feb 12, 2025 | 5.22% | Previous Equal-Weight Current Equal-Weight | |||
Feb 3, 2025 | 22.13% | Previous Initiates Current Buy | |||
Jan 14, 2025 | 57.84% | Previous Buy Current Buy | |||
Jan 7, 2025 | 59.71% | Previous Buy Current Buy | |||
Dec 20, 2024 | 61.59% | Previous Market Outperform Current Market Outperform | |||
Dec 10, 2024 | 76.63% | Previous Buy Current Buy | |||
Nov 6, 2024 | -0.41% | Previous Sector Perform Current Sector Perform | |||
Nov 6, 2024 | 3.34% | Previous Equal-Weight Current Equal-Weight | |||
Nov 6, 2024 | 57.84% | Previous Buy Current Buy | |||
Oct 4, 2024 | -0.41% | Previous Sector Perform Current Sector Perform | |||
Aug 12, 2024 | 87.9% | Previous Buy Current Buy | |||
Aug 8, 2024 | — | — | Previous Current Neutral | ||
Aug 6, 2024 | 10.86% | Previous Hold Current Hold | |||
Aug 6, 2024 | 10.86% | Previous Equal-Weight Current Equal-Weight | |||
Aug 6, 2024 | 12.74% | Previous Sector Perform Current Sector Perform | |||
Aug 6, 2024 | 76.63% | Previous Buy Current Buy | |||
Aug 6, 2024 | 57.84% | Previous Buy Current Buy | |||
Jun 28, 2024 | — | — | Previous Current Neutral | ||
Jun 27, 2024 | 65.35% | Previous Buy Current Buy | |||
Jun 17, 2024 | 97.29% | Previous Overweight Current Overweight | |||
Jun 17, 2024 | 65.35% | Previous Buy Current Buy | |||
May 23, 2024 | 57.84% | Previous Buy Current Buy | |||
May 10, 2024 | 78.5% | Previous Outperform Current Outperform | |||
May 9, 2024 | 61.59% | Previous Market Outperform Current Market Outperform | |||
May 9, 2024 | 22.13% | Previous Equal-Weight Current Equal-Weight | |||
May 9, 2024 | — | — | Previous Current Neutral | ||
May 9, 2024 | 25.89% | Previous Equal-Weight Current Equal-Weight | |||
May 9, 2024 | 65.35% | Previous Buy Current Buy | |||
May 9, 2024 | -2.29% | Previous Neutral Current Neutral | |||
Apr 18, 2024 | 67.23% | Previous Buy Current Buy | |||
Apr 11, 2024 | 69.11% | Previous Buy Current Buy | |||
Mar 6, 2024 | 86.02% | Previous Buy Current Buy | |||
Feb 26, 2024 | -9.81% | Previous Underweight Current Underweight | |||
Feb 22, 2024 | 24.01% | Previous Sector Perform Current Sector Perform | |||
Feb 22, 2024 | 31.53% | Previous Equal-Weight Current Equal-Weight | |||
Feb 22, 2024 | 50.32% | Previous Equal-Weight Current Equal-Weight | |||
Feb 22, 2024 | 110.45% | Previous Buy Current Buy | |||
Feb 21, 2024 | 69.11% | Previous Buy Current Buy | |||
Feb 15, 2024 | — | — | Previous Initiates Current Peer Perform | ||
Dec 11, 2023 | 7.1% | Previous Sector Perform Current Sector Perform | |||
Dec 11, 2023 | 200.64% | Previous Buy Current Buy | |||
Dec 11, 2023 | 14.62% | Previous Equal-Weight Current Equal-Weight | |||
Dec 11, 2023 | -43.63% | Previous Market Perform Current Underperform | |||
Dec 11, 2023 | 50.32% | Previous Market Outperform Current Market Outperform | |||
Dec 11, 2023 | 65.35% | Previous Buy Current Buy | |||
Dec 8, 2023 | 313.38% | Previous Buy Current Buy | |||
Dec 8, 2023 | 54.08% | Previous Buy Current Buy | |||
Dec 5, 2023 | 39.05% | Previous Market Outperform Current Market Outperform | |||
Nov 13, 2023 | -21.08% | Previous Underweight Current Underweight | |||
Nov 7, 2023 | -6.05% | Previous Sector Perform Current Sector Perform | |||
Nov 7, 2023 | 59.71% | Previous Buy Current Buy | |||
Nov 1, 2023 | 65.35% | Previous Buy Current Buy | |||
Oct 30, 2023 | 65.35% | Previous Buy Current Buy | |||
Oct 17, 2023 | — | — | Previous Overweight Current Neutral | ||
Sep 27, 2023 | 54.08% | Previous Initiates Current Buy | |||
Aug 18, 2023 | 31.53% | Previous Neutral Current Buy | |||
Aug 17, 2023 | 31.53% | Previous Neutral Current Buy | |||
Aug 14, 2023 | -19.2% | Previous Underweight Current Underweight | |||
Aug 10, 2023 | 91.66% | Previous Outperform Current Outperform |
FAQ
What is the target price for CRISPR Therapeutics (CRSP) stock?
The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Chardan Capital on November 26, 2025. The analyst firm set a price target for $74.00 expecting CRSP to rise to within 12 months (a possible 39.05% upside). 47 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?
The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by Chardan Capital, and CRISPR Therapeutics maintained their buy rating.
When was the last upgrade for CRISPR Therapeutics (CRSP)?
The last upgrade for CRISPR Therapeutics AG happened on February 14, 2025 when Evercore ISI Group raised their price target to $99. Evercore ISI Group previously had an in-line for CRISPR Therapeutics AG.
When was the last downgrade for CRISPR Therapeutics (CRSP)?
The last downgrade for CRISPR Therapeutics AG happened on June 27, 2025 when Clear Street changed their price target from N/A to $45 for CRISPR Therapeutics AG.
When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on November 26, 2025 so you should expect the next rating to be made available sometime around November 26, 2026.
Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?
While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a maintained with a price target of $82.00 to $74.00. The current price CRISPR Therapeutics (CRSP) is trading at is $53.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
